Epidermal growth factor receptor (EGFR) exon 20 insertions occur rarely among different cancer types, with the highest frequency reported among non-small-cell lung cancer (NSCLC) patients, particularly adenocarcinomas (ADCs). Exon 20 insertions fall back in the tyrosine kinase domain, and can be clustered into two principal groups represented by in frame insertions and three to 21 bp (corresponding to 1–7 amino acids) duplications within amino acids 762 and 774. The identification of these alterations is key for an adequate management of NSCLC patients due to the possibility to treat these patients with specific targeted therapies. Next generation sequencing (NGS) technology, able to detect several hotspot gene mutations for different patients simultaneously, is the best detection approach due to its higher sensitivity and specificity compared to other techniques. Here we reviewed the principal biological characteristics, the main detection technologies and treatment options for NSCLC patients harbouring EGFR exon 20 insertions.

Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients / Malapelle, U.; Pilotto, S.; Reale, M. L.; Passiglia, F.; Pisapia, P.; Pepe, F.; Belluomini, L.; Galetta, D.; Cortinovis, D.; Tiseo, M.; Passaro, A.; Seminati, D.; Pagni, F.; Parra, H. S.; Migliorino, M. R.; Rocco, D.; Troncone, G.; Novello, S.. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - 169:(2022), p. 103536.103536. [10.1016/j.critrevonc.2021.103536]

Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients

Tiseo M.
Membro del Collaboration Group
;
2022

Abstract

Epidermal growth factor receptor (EGFR) exon 20 insertions occur rarely among different cancer types, with the highest frequency reported among non-small-cell lung cancer (NSCLC) patients, particularly adenocarcinomas (ADCs). Exon 20 insertions fall back in the tyrosine kinase domain, and can be clustered into two principal groups represented by in frame insertions and three to 21 bp (corresponding to 1–7 amino acids) duplications within amino acids 762 and 774. The identification of these alterations is key for an adequate management of NSCLC patients due to the possibility to treat these patients with specific targeted therapies. Next generation sequencing (NGS) technology, able to detect several hotspot gene mutations for different patients simultaneously, is the best detection approach due to its higher sensitivity and specificity compared to other techniques. Here we reviewed the principal biological characteristics, the main detection technologies and treatment options for NSCLC patients harbouring EGFR exon 20 insertions.
Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients / Malapelle, U.; Pilotto, S.; Reale, M. L.; Passiglia, F.; Pisapia, P.; Pepe, F.; Belluomini, L.; Galetta, D.; Cortinovis, D.; Tiseo, M.; Passaro, A.; Seminati, D.; Pagni, F.; Parra, H. S.; Migliorino, M. R.; Rocco, D.; Troncone, G.; Novello, S.. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - 169:(2022), p. 103536.103536. [10.1016/j.critrevonc.2021.103536]
File in questo prodotto:
File Dimensione Formato  
Epidermal growth factor receptor exon 20 insertion variants in NSCLC cancer patients POST-PRINT.pdf

embargo fino al 18/11/2022

Descrizione: Articolo principale
Tipologia: Documento in Post-print
Licenza: Creative commons
Dimensione 280.15 kB
Formato Adobe PDF
280.15 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2908939
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 2
social impact